Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections


On 15 August 2018, top-line results from the phase 3 ATLAS study reported that monthly injections with the dual long-acting formulation cabotegravir/rilpivirine were non-inferior as a switch option compared to remaining on triple-drug ART.

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study randomised 570 HIV positive adults who had been virally suppressed for more than six months on their first or second HIV combination.